Trials / Completed
CompletedNCT06461598
Signature for Precise Chemosensitivity Prediction in PDAC
Development and Validation of the ChemoResist Signature Precisely Predictive of Chemotherapy Sensitivity in Resected Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 365 (actual)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Pancreatic ductal adenocarcinoma (PDAC) is largely heterogeneous. We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC. Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3K/AKT/mTOR pathway markers were examined in consecutive patients with PDAC. A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model, and validated in two independent cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chemotherapy | All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1). |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2020-03-16
- Completion
- 2021-05-31
- First posted
- 2024-06-17
- Last updated
- 2024-06-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06461598. Inclusion in this directory is not an endorsement.